Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.
Ortega-Ferreira C, Soret P, Robin G, Speca S, Hubert S, Le Gall M, Desvaux E, Jendoubi M, Saint-Paul J, Chadli L, Chomel A, Berger S, Nony E, Neau B, Fould B, Licznar A, Levasseur F, Guerrier T, Elouej S, Courtade-Gaïani S, Provost N, Nguyen TQ, Verdier J, Launay D, De Ceuninck F. Ortega-Ferreira C, et al. Among authors: de ceuninck f. Nat Commun. 2023 Aug 31;14(1):5291. doi: 10.1038/s41467-023-41117-9. Nat Commun. 2023. PMID: 37652913 Free PMC article.
Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5.
Clement-Lacroix P, Little CB, Smith MM, Cottereaux C, Merciris D, Meurisse S, Mollat P, Touitou R, Brebion F, Gosmini R, De Ceuninck F, Botez I, Lepescheux L, van der Aar E, Christophe T, Vandervoort N, Blanqué R, Comas D, Deprez P, Amantini D. Clement-Lacroix P, et al. Among authors: de ceuninck f. Osteoarthritis Cartilage. 2022 Feb;30(2):291-301. doi: 10.1016/j.joca.2021.08.012. Epub 2021 Oct 6. Osteoarthritis Cartilage. 2022. PMID: 34626798 Free article.
Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA).
Prudhomme V, Cucca M, Nauton L, Andrieu E, Fereyrolles M, Lamoine S, Michelin C, Bennis K, Collin A, De Ceuninck F, Botez I, Mallet C, Ducki S. Prudhomme V, et al. Among authors: de ceuninck f. Eur J Med Chem. 2022 Dec 15;244:114809. doi: 10.1016/j.ejmech.2022.114809. Epub 2022 Oct 1. Eur J Med Chem. 2022. PMID: 36208509
S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.
Duguet F, Ortega-Ferreira C, Fould B, Darville H, Berger S, Chomel A, Leclerc G, Kisand K, Haljasmägi L, Hayday AC, Desvaux E, Nony E, Moingeon P, De Ceuninck F. Duguet F, et al. Among authors: de ceuninck f. J Transl Autoimmun. 2021 Mar 1;4:100093. doi: 10.1016/j.jtauto.2021.100093. eCollection 2021. J Transl Autoimmun. 2021. PMID: 33748735 Free PMC article.
Applications of transcriptomics in support of drug development for osteoarthritis.
Kaplon H, Luo Y, De Ceuninck F, Lalande A, Courtade-Gaiani S, Laigle L, Moingeon P. Kaplon H, et al. Among authors: de ceuninck f. Osteoarthr Cartil Open. 2021 Nov 18;3(4):100221. doi: 10.1016/j.ocarto.2021.100221. eCollection 2021 Dec. Osteoarthr Cartil Open. 2021. PMID: 36474760 Free PMC article.
Targeting galectin-3 in inflammatory and fibrotic diseases.
Bouffette S, Botez I, De Ceuninck F. Bouffette S, et al. Among authors: de ceuninck f. Trends Pharmacol Sci. 2023 Aug;44(8):519-531. doi: 10.1016/j.tips.2023.06.001. Epub 2023 Jun 28. Trends Pharmacol Sci. 2023. PMID: 37391294 Free article. Review.
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease.
Hubert S, Kök-Carrière A, De Ceuninck F. Hubert S, et al. Among authors: de ceuninck f. Trends Pharmacol Sci. 2024 Oct;45(10):941-942. doi: 10.1016/j.tips.2024.08.002. Epub 2024 Sep 10. Trends Pharmacol Sci. 2024. PMID: 39261228 No abstract available.
44 results